Y-1 Syngeneic Model Service for Adrenocortical Tumor

The Y-1 syngeneic model service for adrenocortical tumor is a murine transplantable-tumor platform in which the steroid-secreting Y-1 adrenocortical line is engrafted into compatible hosts, combining tumor-growth assessment with a living endocrine readout — ACTH-responsive steroid production — in a single study. Alfa Cytology provides this model as a fully managed preclinical capability — covering authenticated Y-1 expansion and cell banking, standardized flank or orthotopic-compatible implantation, scheduled tumor-growth and serum-steroid monitoring, and complete endocrine-focused histopathology — all configured around each sponsor’s mechanism of action and pharmacodynamic needs.

Overview of Y-1 Syngeneic Model for Adrenocortical Tumor

Y-1 is the founding member of all adrenocortical cell culture — the first continuously cultured adrenocortical tumor line ever established. Described in 1966 by Yasumura, Buonassisi, and Sato, it was cloned from a transplantable adrenocortical tumor that arose in the right adrenal gland of a male LAF1 mouse — a strain exposed to radiation during the 1951 Operation Greenhouse atomic tests, though whether irradiation truly caused the tumor was never resolved. The line is epithelial-like and steroidogenic, doubling in roughly 30–40 hours, and carries a hypodiploid-to-pseudodiploid murine karyotype (modal count near 39–41, with double minutes in most cells). Its steroidogenic pathway is functional but atypical: Y-1 cells lack 21-hydroxylase (CYP21) activity and therefore cannot synthesize corticosterone; instead they convert cholesterol to pregnenolone and onward to progesterone derivatives — principally 20α-dihydroxyprogesterone and 11β,20α-dihydroxyprogesterone — which they secrete at high rates under maximal stimulation. The MC2R (ACTH receptor) and the canonical cAMP signaling cascade are retained: stimulation with ACTH, forskolin, or cAMP analogs elevates cAMP and steroid output, although the magnitude of the ACTH response has varied between laboratories and the line’s history includes famous signaling-deficient derivatives such as the protein kinase A-deficient Kin-8 mutant and ACTH receptor-deficient clones.

Fig 1. SOS-KRAS-GTP positive feedback loop: Grp4 mRNA expression in Y1 and Y1-FD clones, and in vivo tumor formation in mice showing Y1 cells form tumors while ΔRASGRP4 Y1 (CRISPR-depleted) does not. (Montoni, Fabio, et al., 2026)

As an in vivo model, Y-1 forms steroid-secreting tumors in syngeneic LAF1 hosts — the classical adrenocortical tumor transplant — and engrafts readily in immunodeficient mice for contemporary tumor-biology work. Because every graft carries a working steroidogenic apparatus, studies on this platform can pair tumor-growth kinetics with circulating and tumor-level steroid measurements, converting adrenocortical tumor research into a genuinely endocrine-aware discipline: interventions targeting steroidogenesis enzymes, the SF-1 (steroidogenic factor 1) transcriptional program, or the cAMP signaling axis can be evaluated with both volumetric and hormonal endpoints. The model has served for decades as the baseline against which newer adrenocortical lines (ATC1, ATC7, the human H295R, and PDX-derived lines) are compared, and it remains the reference system for defining how adrenocortical tumors respond to hormonal, enzymatic, and cytotoxic pressure in vivo.

Cell Line Information: Y-1

The table below consolidates the key biological, cultural, and modeling characteristics of the Y-1 line as used in syngeneic and transplantable-tumor studies.

Our Services

Few tumor platforms offer a built-in hormonal pharmacodynamic readout, and Alfa Cytology leverages that advantage fully: authenticated Y-1 banks, standardized implantation into LAF1-compatible or immunodeficient hosts, parallel tumor-growth and serum-steroid monitoring, and endocrine-aware histopathology — all run as one accountable preclinical program.

Workflow of Y-1 Syngeneic Model Construction

Construction follows established transplantable-tumor methodology: Y-1 cells are expanded under authenticated conditions, formulated as a standardized suspension, implanted subcutaneously (or at an organ-adjacent site) into compatible hosts, and followed by growth and steroid-output monitoring with endocrine-focused endpoint analysis. The workflow comprises the following stages.

1. Cell authentication and banking: Y-1 cells are confirmed mycoplasma-free, identity-verified, and expanded into low-passage working banks under standardized Ham’s F-10 culture conditions.
2. Cell harvest and formulation: Healthy cultures are trypsinized, washed, counted and viability-checked, then resuspended at the study-specified dose of approximately 1–5 × 10⁶ cells in 100 μL of PBS or a 1:1 PBS/Matrigel mixture kept on ice until inoculation.
3. Anesthesia and inoculation: Recipient mice (syngeneic LAF1 where available, otherwise immunodeficient hosts per study design) are anesthetized with isoflurane, and the cell suspension is injected subcutaneously into the flank or into the designated organ-adjacent site.
4. Tumor establishment monitoring: Animals are palpated on a fixed schedule until measurable tumors appear; engraftment day, take rate, and latency are recorded as primary quality indicators.
5. Growth and endocrine monitoring: Tumors are measured with calipers on a twice-weekly cadence, while serum or plasma steroid levels are sampled in parallel to capture the graft’s endocrine output over time.
6. Intervention and endpoint analysis: Experimental arms — steroidogenesis inhibitors, SF-1/cAMP-pathway agents, cytotoxic and combination regimens — proceed per study design; endpoints integrate final tumor weight and volume with serum-steroid kinetics and histopathology (H&E, Ki67, SF-1, StAR, and steroidogenic-enzyme immunohistochemistry, with lipid-droplet staining where indicated).

Fig 2. Y-1 Syngeneic Model construction workflow.

Case Study-Y-1 Syngeneic Model Development

Alfa Cytology has conducted preclinical programs on the Y-1 platform spanning steroidogenesis-inhibitor evaluation, SF-1/cAMP-pathway agent testing, and combination regimen assessment in adrenocortical tumor settings. In these studies, implanted Y-1 tumors were tracked by scheduled caliper measurement with parallel serum-steroid sampling, and endpoint histopathology confirmed tumor morphology and steroidogenic-marker expression. Study-level datasets are available upon request.

Why Choose Alfa Cytology?

Alfa Cytology combines endocrine-aware study design with disciplined execution across cell banking, implantation, and histopathology, so every Y-1 syngeneic study delivers paired volumetric and hormonal evidence sponsors can act on.

• Specialized handling of steroidogenic tumor lines, with parallel tumor-growth and serum-steroid readouts built into every design.
• A single coordinated team managing cell banking, implantation, endocrine sampling, and pathology under one quality framework.
• Flexible hosts and dosing schedules matched to mechanism of action, from steroidogenesis inhibitors to cytotoxic combinations.
• Endpoint panels pairing H&E and Ki67 with SF-1, StAR, and steroidogenic-enzyme immunohistochemistry.
• Transparent milestone reporting and rapid scientific feedback throughout the engagement.

Contact Us

If your adrenocortical tumor program needs a transplantable model with a built-in endocrine readout, Alfa Cytology is ready to support you. Reach out to us with your compound profile and pharmacodynamic requirements, or contact us today for a customized proposal and quotation for the Y-1 syngeneic model service.

For research use only. Not intended for any clinical use.